Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar;63(1):74-79.
doi: 10.1097/GRF.0000000000000497.

Advanced Ovarian Cancer: Weighing the Risks and Benefits of Surgery

Amanika Kumar  1 , William A Cliby
Affiliations
Review

Advanced Ovarian Cancer: Weighing the Risks and Benefits of Surgery

Amanika Kumar et al. Clin Obstet Gynecol. 2020 Mar.

Abstract

Treatment for patients with advanced ovarian cancer includes a combination of platinum-based chemotherapy and maximally cytoreductive surgery. The 2 options for initial treatment include upfront surgery followed by adjuvant chemotherapy or neoadjuvant chemotherapy followed by interval surgery. Deciding between which approach is a on the basis of several factors: (1) resectability of disease; (2) patient factors such as age, albumin, and body mass index; (3) patient wishes; and (4) overall functional status. Research is needed to further refine these approaches and create a patient-focused treatment plan which includes novel factors such as molecular subtype of disease and frailty and sarcopenia.

PubMed Disclaimer

References

    1. Wright AA, Bohlke K, Armstrong DK, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guidelines. Gynecol Oncol. 2016;143:3–15.
    1. Wallace S, Kumar A, Gree M, et al. Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resectin is not feasible. Gynecol Oncol. 2017;145:21–26.
    1. Sioulas VD, Schiavone MB, Kadouri D, et al. Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy. Gynecol Oncol. 2017;145:15–20.
    1. Zighelboim I, Kizer N, Taylor NP, et al. “Surgical Apgar Score” predicts postoperative complications after cytoreduction for advanced ovarian cancer. Gynecol Oncol. 2010;116:370–373.
    1. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–1259.

MeSH terms